Sanofi's pill becomes first US-approved drug for rare neurological disorder
SNY•The FDA approved Sanofi's Infilbray, the first treatment for the neurological form of type 3 Gaucher disease. Approval covers adults and children weighing at least 15 kilograms and was based on a 43-patient late-stage study.
1. FDA approves Infilbray
The FDA approved Sanofi's oral drug venglustat, branded as Infilbray, to treat type 3 Gaucher disease, a rare genetic condition affecting the brain and nervous system. The approval covers adults and children weighing at least 15 kilograms. In a late-stage study of 43 patients aged 12 and older, those taking Infilbray once daily for 52 weeks improved on a combined measure of muscle control, coordination and thinking ability compared with patients receiving enzyme replacement therapy every two weeks.
2. Warnings and treatment context
The FDA said commonly reported side effects included digestive problems and changes in mood, and warned of serious psychiatric risks, including suicidal thoughts and behavior. Animal studies identified potential vision clouding in younger patients and adverse effects on fetal development when the drug is taken during pregnancy. Sanofi already sells Cerdelga for type 1 Gaucher disease and Cerezyme for symptoms outside the brain and nervous system in patients with types 1 and 3.




